These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 7833947

  • 1. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.
    de Knijff P, van den Maagdenberg AM, Frants RR, Havekes LM.
    Hum Mutat; 1994; 4(3):178-94. PubMed ID: 7833947
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
    Smelt AH, de Beer F.
    Semin Vasc Med; 2004 Aug; 4(3):249-57. PubMed ID: 15630634
    [Abstract] [Full Text] [Related]

  • 3. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
    de Knijff P, van den Maagdenberg AM, Boomsma DI, Stalenhoef AF, Smelt AH, Kastelein JJ, Marais AD, Frants RR, Havekes LM.
    J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Genetics of type III hyperlipoproteinemia.
    Feussner G, Piesch S, Dobmeyer J, Fischer C.
    Genet Epidemiol; 1997 Sep; 14(3):283-97. PubMed ID: 9181357
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Effect of apolipoprotein E gene plasma levels of lipids, lipoproteins, apolipoproteins and its relation with coronary heart disease].
    Zhu T, Wang Z, Zhao S.
    Hunan Yi Ke Da Xue Xue Bao; 1998 Sep; 23(2):149-51. PubMed ID: 10681829
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE, Li X, van Dijk KW, Havekes LM, Zannis VI.
    Biochemistry; 2003 Aug 26; 42(33):9841-53. PubMed ID: 12924933
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.